PureTech’s Deupirfenidone Demonstrates Superior Efficacy in Slowing Lung Function Decline in Idiopathic Pulmonary Fibrosis (IPF) Patients

Efficacy:
Deupirfenidone showed an 80.9% treatment effect in slowing lung function decline in IPF patients, significantly outperforming the current standard treatment, pirfenidone, which had a 54.1% effect13.

Clinical Trial:
The ELEVATE IPF Phase 2b trial achieved its primary and key secondary endpoints, demonstrating a 98.5% probability of superiority over placebo in slowing lung function decline as measured by FVC13.

Dose-Dependent Response:
The higher dose of deupirfenidone (825 mg TID) showed a more significant effect, reducing lung function decline to near-physiologic levels over 26 weeks13.

Tolerability:
Both doses of deupirfenidone demonstrated favorable tolerability with comparable gastrointestinal adverse events to pirfenidone13.

Future Development:
PureTech plans to advance deupirfenidone rapidly, aiming to deliver a new standard of care to IPF patients while generating value for shareholders1.

Sources:

1. https://www.stocktitan.net/news/PRTC/pure-tech-s-deupirfenidone-lyt-100-slowed-lung-function-decline-in-spoacslaqbxm.html

3. https://news.puretechhealth.com/news-releases/news-release-details/puretechs-deupirfenidone-lyt-100-slowed-lung-function-decline